139 related articles for article (PubMed ID: 10841787)
21. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice.
Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y; Iizumi Y
Jpn J Pharmacol; 1998 Oct; 78(2):191-7. PubMed ID: 9829622
[TBL] [Abstract][Full Text] [Related]
22. Anticoagulant and antithrombotic action of the factor Xa inhibitor antistasin (ATS).
Hauptmann J; Kaiser B
Thromb Res; 1993 Jul; 71(2):169-74. PubMed ID: 8362380
[No Abstract] [Full Text] [Related]
23. Influence of molecular weight of chemically sulfated citrus pectin fractions on their antithrombotic and bleeding effects.
Cipriani TR; Gracher AH; de Souza LM; Fonseca RJ; Belmiro CL; Gorin PA; Sassaki GL; Iacomini M
Thromb Haemost; 2009 May; 101(5):860-6. PubMed ID: 19404539
[TBL] [Abstract][Full Text] [Related]
24. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
25. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
[TBL] [Abstract][Full Text] [Related]
26. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
[TBL] [Abstract][Full Text] [Related]
27. Biochemistry and pharmacology of low molecular weight heparin.
Rosenberg RD
Semin Hematol; 1997 Oct; 34(4 Suppl 4):2-8. PubMed ID: 9399404
[No Abstract] [Full Text] [Related]
28. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Iwatsuki Y; Sato T; Moritani Y; Shigenaga T; Suzuki M; Kawasaki T; Funatsu T; Kaku S
Eur J Pharmacol; 2011 Dec; 673(1-3):49-55. PubMed ID: 22040919
[TBL] [Abstract][Full Text] [Related]
29. Antithrombotic activity and its relationship to in vitro anticoagulant effects.
Gray E; Padilla A; Barrowcliffe TW
Haemostasis; 1993 Mar; 23 Suppl 1():99-102. PubMed ID: 8388358
[TBL] [Abstract][Full Text] [Related]
30. Anticoagulant and antithrombotic evaluation of native fucosylated chondroitin sulfates and their derivatives as selective inhibitors of intrinsic factor Xase.
Wu M; Wen D; Gao N; Xiao C; Yang L; Xu L; Lian W; Peng W; Jiang J; Zhao J
Eur J Med Chem; 2015 Mar; 92():257-69. PubMed ID: 25559206
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of thrombin generation in plasma by inhibitors of factor Xa.
Prasa D; Svendsen L; Stürzebecher J
Thromb Haemost; 1997 Oct; 78(4):1215-20. PubMed ID: 9364987
[TBL] [Abstract][Full Text] [Related]
32. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
Sun X; Hong Z; Liu M; Guo S; Yang D; Wang Y; Lan T; Gao L; Qi H; Gong P; Liu Y
Bioorg Med Chem; 2017 May; 25(10):2800-2810. PubMed ID: 28389110
[TBL] [Abstract][Full Text] [Related]
34. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Wong PC; Quan ML; Crain EJ; Watson CA; Wexler RR; Knabb RM
J Pharmacol Exp Ther; 2000 Jan; 292(1):351-7. PubMed ID: 10604970
[TBL] [Abstract][Full Text] [Related]
35. The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.
Hirayama F; Koshio H; Katayama N; Kurihara H; Taniuchi Y; Sato K; Hisamichi N; Sakai-Moritani Y; Kawasaki T; Matsumoto Y; Yanagisawa I
Bioorg Med Chem; 2002 May; 10(5):1509-23. PubMed ID: 11886813
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in the discovery and development of direct coagulation factor Xa inhibitors.
Gould WR; Leadley RJ
Curr Pharm Des; 2003; 9(28):2337-47. PubMed ID: 14529395
[TBL] [Abstract][Full Text] [Related]
37. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
38. [New anticoagulants -- their clinical significance].
Haas S
Ther Umsch; 2003 Jan; 60(1):19-23. PubMed ID: 12638473
[TBL] [Abstract][Full Text] [Related]
39. Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities.
Stefanic Anderluh P; Anderluh M; Ilas J; Mravljak J; Sollner Dolenc M; Stegnar M; Kikelj D
J Med Chem; 2005 May; 48(9):3110-3. PubMed ID: 15857114
[TBL] [Abstract][Full Text] [Related]
40. Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors.
Quan ML; Wong PC; Wang C; Woerner F; Smallheer JM; Barbera FA; Bozarth JM; Brown RL; Harpel MR; Luettgen JM; Morin PE; Peterson T; Ramamurthy V; Rendina AR; Rossi KA; Watson CA; Wei A; Zhang G; Seiffert D; Wexler RR
J Med Chem; 2014 Feb; 57(3):955-69. PubMed ID: 24405333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
